Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.53 |
| ▸ | PPARA | Q07869 | 3/20 | 0.53 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | CCNC | P24863 | 2/20 | 0.42 |
| ▸ | CDK8 | P49336 | 2/20 | 0.42 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | PORCN | Q9H237 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | PRMT3 | O60678 | 2/20 | 0.38 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.37 |
| ▸ | IKBKB | O14920 | 1/20 | 0.37 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.37 |
| ▸ | MELK | Q14680 | 1/20 | 0.37 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8363966 | 0.87 | PPARG (0.71) | PPARGPPARAMRGPRX4CACNA2D1NOTUM | |
| SCHEMBL2073059 | 0.86 | PPARG (0.69) | PPARGPPARAMRGPRX4CACNA2D1NOTUM | |
| SCHEMBL2073068 | 0.86 | PPARG (0.69) | PPARGPPARAMRGPRX4CACNA2D1NOTUM | |
| SCHEMBL2073061 | 0.85 | PPARG (0.56) | PPARGPPARAMRGPRX4CACNA2D1NOTUM | |
| SCHEMBL10722909 | 0.84 | PPARG (0.74) | PPARGPPARAARALDH2 | |
| SCHEMBL11128812 | 0.75 | GAA (0.53) | MRGPRX4NOTUMPORCNCYP3A4 | |
| SCHEMBL8358819 | 0.75 | KDM4E (0.48) | PPARGPPARAMRGPRX4CACNA2D1NOTUM | |
| SCHEMBL6482624 | 0.74 | PPARG (0.49) | PPARGPPARAMRGPRX4CACNA2D1NOTUM | |
| SCHEMBL6482619 | 0.74 | PPARG (0.49) | PPARGPPARAMRGPRX4CACNA2D1NOTUM | |
| Ethyl Acetate SCHEMBL29093043 | 0.74 | ALDH1A1 (0.48) | MRGPRX4CCNCCDK8CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414456-B1 | PHENYL DERIVATIVES AS FACTOR XA INHIBITORS | MERCK PATENT GMBH (DE) | 2011-12-28 | — | — | EP | disclosed |
| EP-1414456-B1 | PHENYL DERIVATIVES AS FACTOR XA INHIBITORS | MERCK PATENT GMBH (DE) | 2011-12-28 | — | — | EP | disclosed |
| US-7902223-B2 | For therapy and prophylaxis of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexia, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases | MERCK PATENT GMBH (DE) | 2011-03-08 | — | — | US | disclosed |
| US-7902223-B2 | For therapy and prophylaxis of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexia, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases | MERCK PATENT GMBH (DE) | 2011-03-08 | — | — | US | disclosed |
| US-7902223-B2 | For therapy and prophylaxis of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexia, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases | MERCK PATENT GMBH (DE) | 2011-03-08 | — | — | US | disclosed |
| US-20040235828-A1 | Phenyl derivatives as factor XA Inhibitors | MERCK PATENTGESELLSCHAFT (DE) | 2004-11-25 | — | — | US | disclosed |
| WO-2003013531-A1 | PHENYL DERIVATIVES AS FACTOR XA INHIBITORS | MERCK PATENT GMBH (DE) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235828-A1 | Phenyl derivatives as factor XA Inhibitors | F11, F2, F12 | PPARG 2943/4885PPARA 3586/4885MRGPRX4 786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.